United Therapeutics
UTHR | NASDAQ
$587.88
-$3.29 (-0.56%)
At close: Nov 16, 2026, 4:00 PM ET
$587.88
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
United Therapeutics Company Profile
Company profile explainedCompany Profile
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Key Executives
| Name | Position |
|---|---|
| Martine A. Rothblatt | Founder, Chairman & Chief Executive Officer |
| James C. Edgemond | Chief Financial Officer & Treasurer |
| Michael I. Benkowitz | President & Chief Operating Officer |
| Gil Golden | Senior Vice President & Chief Medical Officer |
| Harrison Silvers | Manager of Investor Relations |
| Holly Hobson | Associate Vice President of Human Resources |
| Leigh Peterson | Executive Vice President of Product Development & Xenotransplantation |
| Patrick Poisson | Executive Vice President of Strategic Development |
| Paul A. Mahon | Executive Vice President, General Counsel & Corporate Secretary |
United Therapeutics
| Country | United States |
| IPO Date | Jun 17, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,400 |
| CEO | Martine A. Rothblatt |
Contact Details
1040 Spring Street Silver Spring,
Maryland 20910 United States
Stock Details
| Ticker Symbol | UTHR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001082554 |
| CUSIP Number | 91307C102 |
| ISIN Number | US91307C1027 |
| SIC Code | 2834 |
Recent News
- 3 hours ago / marketbeat.comUnited Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter
- 18 hours ago / seekingalpha.comUnited Therapeutics Corporation (UTHR) Presents at UBS Global Biopharma Conference 2026 Transcript
- 8 days ago / businesswire.comUnited Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
- 12 days ago / marketbeat.comWhat United Therapeutics (UTHR) Said on Its Q3 Earnings Call
- 13 days ago / seekingalpha.comUnited Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript
- 13 days ago / zacks.comUnited Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
- 13 days ago / zacks.comUnited Therapeutics (UTHR) Q3 Earnings Miss Estimates
- 13 days ago / businesswire.comUnited Therapeutics Announces Buydown of Ralinepag Royalty
- 13 days ago / businesswire.comUnited Therapeutics Corporation Reports Third Quarter 2026 Financial Results
- 20 days ago / zacks.comAnalysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
Add to Watchlist
Select watchlists to add or remove UTHR